西罗莫司对预防初次配型不相合肾移植受者的急性排斥反应有效。 - Suppr

Suppr

超能文献

Sirolimus is effective for prevention of acute rejection in primary mismatched renal allograft recipients.

作者信息

Ponticelli C

机构信息

Divisione di Nefrologia e Dialisi, IRCCS Ospedale Maggiore di Milano, Milano, Italy.

出版信息

Transplant Proc. 2001 Feb-Mar;33(1-2):1031-2. doi: 10.1016/s0041-1345(00)02317-4.

DOI:10.1016/s0041-1345(00)02317-4

PMID:11267177

Abstract

摘要

相似文献

Sirolimus is effective for prevention of acute rejection in primary mismatched renal allograft recipients.

Transplant Proc. 2001 Feb-Mar;33(1-2):1031-2. doi: 10.1016/s0041-1345(00)02317-4.

A retrospective analysis of a sirolimus/prograf regimen for the prevention of acute rejection in recipients of primary mismatched renal allografts.

Transplant Proc. 2002 Aug;34(5):1653-5. doi: 10.1016/s0041-1345(02)02967-6.

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts.

Transplantation. 2001 Jan 27;71(2):271-80. doi: 10.1097/00007890-200101270-00019.

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.

Transplantation. 2000 Apr 15;69(7):1252-60. doi: 10.1097/00007890-200004150-00009.

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group.

Lancet. 2000 Jul 15;356(9225):194-202. doi: 10.1016/s0140-6736(00)02480-6.

Effect of sirolimus in combination with low-dose cyclosporine and steroids on acute renal allograft rejection.

J Formos Med Assoc. 2003 Feb;102(2):91-6.

Sirolimus (rapamycin) reduces the incidence of acute rejection episodes in renal transplantation: an initial experience in Taiwan.

Transplant Proc. 2004 Sep;36(7):2051-2. doi: 10.1016/j.transproceed.2004.08.095.

Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.

Transplantation. 2008 Nov 15;86(9):1187-95. doi: 10.1097/TP.0b013e318187bab0.

Sirolimus: a new agent for prevention of renal allograft rejection.

Am J Health Syst Pharm. 2000 Mar 1;57(5):437-48; quiz 449-51. doi: 10.1093/ajhp/57.5.437.

Sirolimus in combination with tacrolimus or mycophenolate mofetil for minimizing acute rejection risk in renal transplant recipients--a single center experience.

Transplant Proc. 2003 May;35(3 Suppl):89S-94S. doi: 10.1016/s0041-1345(03)00220-3.

引用本文的文献

Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.

Cochrane Database Syst Rev. 2019 Dec 16;12(12):CD004290. doi: 10.1002/14651858.CD004290.pub3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Sirolimus is effective for prevention of acute rejection in primary mismatched renal allograft recipients.

作者信息

Ponticelli C

机构信息

Divisione di Nefrologia e Dialisi, IRCCS Ospedale Maggiore di Milano, Milano, Italy.

出版信息

Transplant Proc. 2001 Feb-Mar;33(1-2):1031-2. doi: 10.1016/s0041-1345(00)02317-4.

DOI:10.1016/s0041-1345(00)02317-4

PMID:11267177

Abstract

摘要